KR20040073501A - 신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제 - Google Patents
신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제 Download PDFInfo
- Publication number
- KR20040073501A KR20040073501A KR10-2004-7009750A KR20047009750A KR20040073501A KR 20040073501 A KR20040073501 A KR 20040073501A KR 20047009750 A KR20047009750 A KR 20047009750A KR 20040073501 A KR20040073501 A KR 20040073501A
- Authority
- KR
- South Korea
- Prior art keywords
- purin
- amine
- active ingredient
- fludara
- arabinofuranosyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (12)
- 플루다라 중의 오염물질들이 하기의 분율을 초과하지 않는 것을 특징으로 하는, 락토오스 일수화물, 콜로이드성 이산화규소, 미세결정질 셀룰루오스 (아비셀), 크로스카라멜로스-Na (나트륨 카르복시메틸 셀룰로오스) 및 스테아르산 마그네슘과 함께 순도가 99.19%를 초과하는 활성 성분 플루다라를 1 내지 100 mg 포함하는 신속-방출 정제 제제:2-플루오로-9-(β-D-아라비노푸라노실)-9H-푸린-6-아민 0.02%,6-아미노-9(5-O-포스포노-β-D-아라비노푸라노실)-9H-푸린-2-올 0.12%,2-플루오로-9H-푸린-6-아민 0.02%,6-아미노-9H-푸린-2-올 0.02%,2-플루오로-9-(5-O-포스포노-β-D-리보푸라노실)-9H-푸린-6-아민 0.05%,9-(3,5-O-디포스포노-β-D-아라비노푸라노실)-2-플루오로-9H-푸린-6-아민 0.1%,9-(2,5-O-디포스포노-β-D-아라비노푸라노실)-2-플루오로-9H-푸린-6-아민 0.1%,2-플루오로-9-(5-O-포스포노-β-D-아라비노푸라노실)-9H-푸린-6-아민 0.02%,2-에톡시-9-(5-O-포스포노-β-D-아라비노푸라노실)-9H-푸린-6-아민 0.06%,2-(6-아미노-9H-푸린-2-일)-9-(5-O-포스포노-β-D-아라비노푸라노실)-9H-푸린-6-아민 및 O,O'-비스[2-(6-아미노-2-플루오로-9H-푸린-9-일)-5-데옥시-α-D-아라비노푸라노스-5-일]-포스페이트 0.02%,9-(2-클로로-2-데옥시-5-포스포노-β-D-아라비노푸라노실)-2-플루오로-9H-푸린-6-아민 0.1% 및9-(2,5-안히드로-β-D-아라비노푸라노실)-2-플루오로-9H-푸린-6-아민 0.1%.
- 제1항에 있어서, 락토오스 일수화물 50 내지 100 mg, 콜로이드성 이산화규소 0.1 내지 5 mg, 미세결정질 셀룰루오스 (아비셀) 40 내지 100 mg, 크로스카라멜로스-Na (나트륨 카르복시메틸 셀룰로오스) 1 내지 10 mg 및 스테아르산 마그네슘 0.5 내지 10 mg과 함께 순도가 99.19%를 초과하는 활성 성분 플루다라를 1 내지 70 mg 포함하는 신속-방출 정제 제제.
- 제1항 또는 제2항에 있어서, 락토오스 일수화물 60 내지 90 mg, 콜로이드성 이산화규소 0.5 내지 1 mg, 미세결정질 셀룰루오스 (아비셀) 50 내지 90 mg, 크로스카라멜로스-Na (나트륨 카르복시메틸 셀룰로오스) 1.5 내지 5 mg 및 스테아르산 마그네슘 1 내지 3 mg과 함께 순도가 99.19%를 초과하는 활성 성분 플루다라를 1 내지 50 mg 포함하는 신속-방출 정제 제제.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 락토오스 일수화물 74.75 mg, 콜로이드성 이산화규소 0.75 mg, 미세결정질 셀룰루오스 (아비셀) 60.00 mg, 크로스카라멜로스-Na (나트륨 카르복시메틸 셀룰로오스) 3.00 mg 및 스테아르산 마그네슘1.5 내지 2.00 mg과 함께 순도가 99.19%를 초과하는 활성 성분 플루다라를 10 mg 포함하는 신속-방출 정제 제제.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 순도가 99.37%를 초과하는 활성 성분 플루다라를 포함하는 신속-방출 정제 제제.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 순도가 99.57%를 초과하는 활성 성분 플루다라를 포함하는 신속-방출 정제 제제.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 순도가 99.80%를 초과하는 활성 성분 플루다라를 포함하는 신속-방출 정제 제제.
- 제1항 내지 제7항 중 어느 한 항에 있어서, 순도가 99.85%를 초과하는 활성 성분 플루다라를 포함하는 신속-방출 정제 제제.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 정제 코어가 히드록시프로필 메틸 셀룰로오스 1 내지 5 mg, 탈크 0.1 내지 1 mg, 이산화티탄 0.1 내지 5 mg, 산화철 황색 안료 0.01 내지 0.1 mg 및 산화철 적색 안료 0.01 내지 0.1 mg를 포함하는 코팅에 의해 싸이는 신속-방출 정제 제제.
- 제1항 내지 제9항 중 어느 한 항에 있어서, 히드록시프로필 메틸 셀룰로오스 1 내지 3 mg, 탈크 0.1 내지 0.8 mg, 이산화티탄 0.1 내지 2 mg, 산화철 황색 안료 0.01 내지 0.05 mg 및 산화철 적색 안료 0.01 내지 0.05 mg을 포함하는 코팅에 의해 싸이는 신속-방출 정제 제제.
- 제1항 내지 제10항 중 어느 한 항에 있어서, 히드록시프로필 메틸 셀룰로오스 2.250 mg, 탈크 0.450 mg, 이산화티탄 1.187 mg, 산화철 황색 안료 0.036 mg 및 산화철 적색 안료 0.036 mg을 포함하는 코팅에 의해 싸이는 신속-방출 정제 제제.
- 암 치료용 의약 제조를 위한 제1항 내지 제11항 중 어느 한 항의 정제 제제의 용도.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10164510.4 | 2001-12-20 | ||
DE10164510A DE10164510A1 (de) | 2001-12-20 | 2001-12-20 | Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes |
PCT/EP2002/013252 WO2003053418A1 (de) | 2001-12-20 | 2002-11-25 | Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040073501A true KR20040073501A (ko) | 2004-08-19 |
KR100884685B1 KR100884685B1 (ko) | 2009-02-18 |
Family
ID=7711168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047009750A KR100884685B1 (ko) | 2001-12-20 | 2002-11-25 | 신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제 |
Country Status (30)
Country | Link |
---|---|
US (1) | US7148207B2 (ko) |
EP (1) | EP1455760B1 (ko) |
JP (2) | JP2005519043A (ko) |
KR (1) | KR100884685B1 (ko) |
CN (1) | CN1306929C (ko) |
AR (1) | AR037965A1 (ko) |
AT (1) | ATE303797T1 (ko) |
AU (1) | AU2002349043B2 (ko) |
BR (1) | BR0215265A (ko) |
CA (1) | CA2471396A1 (ko) |
DE (2) | DE10164510A1 (ko) |
DK (1) | DK1455760T3 (ko) |
EC (1) | ECSP045185A (ko) |
ES (1) | ES2248624T3 (ko) |
HK (1) | HK1077741A1 (ko) |
HR (1) | HRP20040648B1 (ko) |
IL (2) | IL162555A0 (ko) |
JO (1) | JO2363B1 (ko) |
MX (1) | MXPA04006005A (ko) |
NO (1) | NO20043063L (ko) |
NZ (1) | NZ533701A (ko) |
PE (1) | PE20030639A1 (ko) |
RS (1) | RS50398B (ko) |
RU (1) | RU2318496C2 (ko) |
SA (1) | SA03240091B1 (ko) |
TW (1) | TWI255187B (ko) |
UA (1) | UA78741C2 (ko) |
UY (1) | UY27596A1 (ko) |
WO (1) | WO2003053418A1 (ko) |
ZA (1) | ZA200405735B (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201190243A1 (ru) * | 2009-05-19 | 2013-01-30 | Гриндекс, Э Джоинт Сток Кампани | Стабильная фармацевтическая композиция флударабина фосфата |
US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
CN101947208B (zh) * | 2010-10-09 | 2012-05-23 | 江苏奥赛康药业股份有限公司 | 一种供注射用的磷酸氟达拉滨组合物及其制备方法 |
CN102091046B (zh) * | 2011-02-12 | 2012-07-18 | 海南锦瑞制药股份有限公司 | 一种磷酸氟达拉滨冻干粉针剂及其制备方法 |
US10669302B2 (en) * | 2015-08-28 | 2020-06-02 | Zhejianf Hisun Pharmaceutical Co., Ltd. | Crystal form of fludarabine phosphate, preparation method therefor, and application thereof |
CN111423458A (zh) * | 2020-04-29 | 2020-07-17 | 东南大学 | 磷酸氟达拉滨杂质h对照品的制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903297A (en) * | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
US4188378A (en) * | 1978-01-04 | 1980-02-12 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine |
US4210745A (en) * | 1978-01-04 | 1980-07-01 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine |
US4357324A (en) * | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
DE3323621A1 (de) * | 1982-07-08 | 1984-03-01 | Yamasa Shoyu K.K., Choshi, Chiba | Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier |
US5110919A (en) * | 1989-12-04 | 1992-05-05 | Ash Stevens, Inc. | Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates |
FR2701027B1 (fr) * | 1993-02-01 | 1997-07-18 | Warner Lambert Co | Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate. |
DE19543052A1 (de) | 1995-11-06 | 1997-05-07 | Schering Ag | Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren |
ATE220543T1 (de) * | 1996-04-23 | 2002-08-15 | Janssen Pharmaceutica Nv | Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid |
CA2210600A1 (en) * | 1996-07-17 | 1998-01-17 | Takashi Houkan | Inhibitor of tumor metastasis or recurrence |
US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
SK283475B6 (sk) * | 1997-12-11 | 2003-08-05 | Schering Aktiengesellschaft | Spôsob výroby lítnych, sodných, draselných, vápenatých a horečnatých solí fludarabín-fosfátu, spôsob čistenia pri výrobe fludarabín-fosfátu a fludarabín-fosfát s čistotou najmenej 99,5 % |
CN1237958C (zh) | 1998-06-11 | 2006-01-25 | 法玛西雅厄普约翰美国公司 | 一种非缓释的、非咀嚼的药物片剂组合物 |
US6174873B1 (en) | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
WO2001014348A1 (en) | 1999-08-20 | 2001-03-01 | The Scripps Research Institute | Formation of heterocycles |
EP1175220B1 (en) | 1999-12-08 | 2005-04-27 | Pharmacia Corporation | Nanoparticulate eplerenone compositions |
US20020131988A1 (en) | 1999-12-16 | 2002-09-19 | Foster Todd P. | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
EP1237555A2 (en) * | 1999-12-16 | 2002-09-11 | PHARMACIA & UPJOHN COMPANY | Implant composition containing melengestrol acetate and trenbolone acetate |
US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
-
2001
- 2001-12-20 DE DE10164510A patent/DE10164510A1/de not_active Ceased
-
2002
- 2002-11-25 ES ES02781328T patent/ES2248624T3/es not_active Expired - Lifetime
- 2002-11-25 AU AU2002349043A patent/AU2002349043B2/en not_active Ceased
- 2002-11-25 EP EP02781328A patent/EP1455760B1/de not_active Expired - Lifetime
- 2002-11-25 WO PCT/EP2002/013252 patent/WO2003053418A1/de active IP Right Grant
- 2002-11-25 CN CNB028279034A patent/CN1306929C/zh not_active Expired - Fee Related
- 2002-11-25 BR BR0215265-7A patent/BR0215265A/pt not_active Application Discontinuation
- 2002-11-25 RS YUP-533/04A patent/RS50398B/sr unknown
- 2002-11-25 CA CA002471396A patent/CA2471396A1/en not_active Abandoned
- 2002-11-25 DE DE50204203T patent/DE50204203D1/de not_active Expired - Lifetime
- 2002-11-25 JP JP2003554177A patent/JP2005519043A/ja active Pending
- 2002-11-25 NZ NZ533701A patent/NZ533701A/xx not_active IP Right Cessation
- 2002-11-25 AT AT02781328T patent/ATE303797T1/de active
- 2002-11-25 KR KR1020047009750A patent/KR100884685B1/ko active IP Right Grant
- 2002-11-25 MX MXPA04006005A patent/MXPA04006005A/es active IP Right Grant
- 2002-11-25 DK DK02781328T patent/DK1455760T3/da active
- 2002-11-25 UA UA20040705884A patent/UA78741C2/uk unknown
- 2002-11-25 IL IL16255502A patent/IL162555A0/xx active IP Right Grant
- 2002-11-25 RU RU2004122479/15A patent/RU2318496C2/ru not_active IP Right Cessation
- 2002-12-10 JO JO2002123A patent/JO2363B1/en active
- 2002-12-19 UY UY27596A patent/UY27596A1/es not_active Application Discontinuation
- 2002-12-20 AR ARP020105054A patent/AR037965A1/es not_active Application Discontinuation
- 2002-12-20 US US10/324,141 patent/US7148207B2/en not_active Expired - Fee Related
- 2002-12-20 TW TW091136814A patent/TWI255187B/zh not_active IP Right Cessation
-
2003
- 2003-01-06 PE PE2003000017A patent/PE20030639A1/es not_active Application Discontinuation
- 2003-04-27 SA SA03240091A patent/SA03240091B1/ar unknown
-
2004
- 2004-06-16 IL IL162555A patent/IL162555A/en not_active IP Right Cessation
- 2004-07-12 EC EC2004005185A patent/ECSP045185A/es unknown
- 2004-07-15 HR HR20040648 patent/HRP20040648B1/xx not_active IP Right Cessation
- 2004-07-19 NO NO20043063A patent/NO20043063L/no not_active Application Discontinuation
- 2004-07-19 ZA ZA2004/05735A patent/ZA200405735B/en unknown
-
2005
- 2005-11-03 HK HK05109796A patent/HK1077741A1/xx not_active IP Right Cessation
- 2005-12-28 JP JP2005379628A patent/JP2006137771A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2000763C (en) | Dispersable formulation | |
EP2068835A2 (en) | Imatinib compositions | |
WO2007011349A1 (en) | Novel granulation process and granulate produced therefrom | |
WO2019073331A2 (en) | PHARMACEUTICAL COMPOSITIONS OF APREMILAST | |
JP2006137771A (ja) | 活性成分の即開放性を有する高純度配合物の経口フルダラ | |
KR20150015500A (ko) | 엔테카비어의 약제학적 조성물 및 제조 방법 | |
JP2012509320A (ja) | テノフォビル、エムトリシタビン及びエファビレンツの湿式造粒法 | |
WO2006134610A1 (en) | Efavirenz pharmaceutical composition having enhanced dissolution profile | |
IL99237A (en) | Preparation of a preparation in the form of a tablet or pill containing a compound sensitive to moisture, heat and light with a monoclinic crystal structure | |
JP4387192B2 (ja) | S−アデノシルメチオニンを含む錠剤の調製方法 | |
KR20100090138A (ko) | 경구용 결핵의 치료용 또는 예방용 고형 제형 | |
KR20160086829A (ko) | 지효성 고체 경구용 조성물 | |
JP2009091362A (ja) | 高含量ファムシクロビル錠剤 | |
JPH026543A (ja) | アルギネートとポリアクリレートの混合物及びその使用 | |
EP1300160B1 (en) | Method of stabilizing preparation | |
EP2117534B1 (en) | A pharmaceutical composition with atorvastatin active ingredient | |
JP7153197B2 (ja) | ナルフラフィンを含有する錠剤化された医薬組成物 | |
KR100422418B1 (ko) | 불용성 약물의 서방형 제제의 제조방법 | |
HUT67577A (en) | Process for production of adsorbate comprising adjuvant-mixture and non-solid active agent using production of preparations | |
WO2023128898A1 (en) | Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients | |
AU2002350564B2 (en) | Process for the preparation of tablets comprising S-adenosylmethionine | |
US20060177501A1 (en) | Film Coated Tablets Containing Ibuprofen | |
PL203451B1 (pl) | Doustny preparat Fludara o najwy zszym stopniu czysto sci o szybkim uwalnianiu substancji czynnej | |
JP2009542806A (ja) | 感湿性薬物及び第2薬物の組合せを含んで成る安定製剤及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130117 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140121 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150119 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170119 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180118 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190116 Year of fee payment: 11 |